Generics Makers Claim Vindication in FTC Report

Drug Industry Daily
A A
Generics makers are claiming vindication after a Federal Trade Commission report found only a single patent case was settled with “pay-for-delay” tactics in fiscal 2016—the lowest level since the government began tracking such settlements.

To View This Article:

Login

Subscribe To Drug Industry Daily